SpecifEx-Hep BAlternative Names: Hepatitis B virus-specific cytotoxic T lymphocytes
Latest Information Update: 08 Aug 2007
At a glance
- Originator CellExSys
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 31 Jan 2007 Discontinued - Preclinical for Hepatitis B treatment in USA (Infusion)
- 10 Aug 2004 CellExSys has been acquired by Chromos Molecular Systems
- 09 Jul 2003 Preclinical trials in Hepatitis B treatment in USA (Infusion)